Table 2.
Line listing of baseline characteristics, treatment and antibody assessment of patients
| Patient number | Age, sex (years; female or male) | Abatacept dose (mg); duration of exposurea (months) | Number of vaccine injections | Duration between last vaccination and abatacept initiation (months) | Duration between last vaccination and antibody sample collection (months) | Blood antibody level to diphtheriab (IU/mL) | Blood antibody level to tetanusb (IU/mL) | Concomitant MTX dosec (mg/m2/week; oral or SC) |
Concomitant prednisone dosec (mg/kg/day) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5, F | 50; 27 | N/A | N/A | N/A | 0.6 | 5.4 | – | – |
| 2 | 3, F | 50; 19 | 4 | 30 | 49 | 0.8 | 0.4 | 7.9, O | – |
| 3 | 3, M | 50; 4 | 4 | 27 | 30 | 0.2 | 0.8 | 16.6, O | – |
| 4 | 5, F | 50; 24 | 4 | −3 | 21d | 0.8 | 2.2 | 15.5, O | – |
| 5 | 5, F | 50; 22 | 5 | N/A | N/A | 0.5 | 4.9 | 3.4, O | – |
| 6 | 5, F | 50; 22 | 4 | 52 | 73 | 0.9 | 1.0 | 9.9, O | – |
| 7 | 4, M | 87.5e; 19 | 4 | 47 | 66 | 0.5 | 5.9 | – | – |
| 8 | 4, M | 50; 19 | 5 | 43 | 62 | 0.7 | 8.2 | 13.1, SC | – |
| 9 | 4, F | 50; 16 | 3 | 52 | 67 | 0.5 | 0.6 | 16.2, SCf | – |
| 10 | 5, M | 50; 19 | 5 | 54 | 72 | 0.7 | 8.3 | 16.0, SC | – |
| 11 | 3, F | 50; 19 | 4 | 36 | 54 | 0.5 | 0.4 | – | – |
| 12 | 4, M | 87.5; 4 | 4 | 35 | 39 | 0.4 | 2.3 | 14.0, O | – |
| 13 | 3, F | 50; 4 | 4 | 30 | 34 | 0.6 | 2.0 | 11.7, SC | – |
| 14 | 4, F | 50; 2 | 4 | 46 | 48 | 0.5 | 1.8 | 10.4, SC | – |
| 15 | 2, F | 50; 2 | 3 | 24 | 26 | 0.6 | 3.1 | 14.3, SC | – |
| 16 | 5, M | 50; 3 | 4 | 57 | 60 | 0.4 | 0.6 | – | – |
| 17 | 5, M | 87.5; 3 | 4 | 57 | 60 | 0.3 | 1.1 | – | – |
| 18 | 2, F | 50; 3 | 4 | 21 | 24 | 0.1 | 0.2 | – | – |
| 19 | 4, F | 50; 3 | 4 | 46 | 49 | 0.5 | 1.4 | 11.5, SC | – |
| 20 | 5, M | 50; 30 | 4 | 49 | 79 | 0.1 | 0.3 | – | – |
| 21 | 5, M | 50; 24 | 5 | 54 | 78 | 1.1 | 5.7 | 10.0, SC | – |
| 22 | 4, F | 87.5e; 24 | 4 | 45 | 69 | 1.5 | 23.2 | – | – |
| 23 | 5, M | 50; 16 | 4 | 31 | 47 | 0.2 | 3.2 | – | – |
| 24 | 4, M | 87.5e; 16 | 4 | 35 | 51 | 0.1 | 1.8 | 11.7, O | – |
| 25 | 5, F | 50; 19 | N/A | N/A | N/A | 0.5 | 0.8 | 22.9, O | 0.1 |
| 26 | 5, F | 87.5e; 19 | N/A | N/A | N/A | 3.8 | 3.8 | 11.5, O | – |
| 27 | 5, M | 50; 19 | N/A | N/A | N/A | 0.6 | 3.3 | 20.1, O | 0.1 |
| 28 | 4, M | 87.5g; 21 | N/A | N/A | N/A | 0.5 | 0.5 | 14.8, O | – |
| 29 | 5, F | 87.5e; 10 | N/A | N/A | N/A | 8.0 | 12.5 | 12.2, O | – |
aAt time of blood sample collection
bProtective antibody threshold > 0.1 IU/mL
cConcurrent medication use assessed at the time of blood sample collection, or at the closest date before with available status
dA single vaccination was administered during the study period after 3 months of abatacept treatment. Antibody sample collection was carried out 21 months after the final vaccination dose was administered
ePatient initiated abatacept 50 mg before dose escalation
fPatient switched from 16.2 mg/m2/week SC MTX to 12.9 mg/m2/week oral MTX on the day of blood sample collection
gPatient initiated abatacept 50 mg, received 5 doses of abatacept at 125 mg before returning to 50 mg, and later escalated to 87.5 mg
F female, M male, MTX methotrexate, N/A not available, O oral, SC subcutaneous